Meta analysis of 25 RCTs showing vitamin D supplementation was safe and it protected against acute respiratory tract infection overall. Patients who were very vitamin D deficient and those not receiving bolus doses experienced the most benefit.
Vitamin D supplementation reduced the risk of acute respiratory tract infection among all participants (adjusted odds ratio aOR 0.88 [0.81-0.96],
p=0.003.
In subgroup analysis, protective effects were seen in those receiving daily or weekly vitamin D without additional bolus doses (aOR 0.81 [0.72-0.91]) but not in those receiving one or more bolus doses (aOR 0.97 [0.86-1.10]). Among those receiving daily or weekly vitamin D, protective effects were stronger in those with baseline 25-hydroxyvitamin D levels <25 nmol/L (aOR 0.30 [0.17-0.53]) than in those with baseline 25-hydroxyvitamin D levels ≥25 nmol/L (aOR 0.75 [0.60-0.95]).
Currently there are
82 vitamin D
for COVID-19 studies, showing 37%
[25‑47%] lower mortality, 32%
[4‑53%] lower ventilation, 50%
[27‑65%] lower ICU admission, 20%
[9‑29%] lower hospitalization, and 12%
[2‑21%] lower cases.
Martineau et al., 1/1/2017, peer-reviewed, 25 authors.